Summary
The effect of the synthetic retinoid acitretin (A) on the disposition of blood glucose and on the serum insulin response following the IV infusion of 139 mmol glucose over 10 min (IGTT) has been investigated in six healthy subjects. The IGTT was performed on Days 1, 10 and 24. On Days 3 to 10 A 50 mg/d was administered. Several parameters of glucose disposition and insulin response (K-values, AUC) were assessed. As a methodological variant, the profiles over time of blood glucose and serum insulin were evaluated by model calculations using the ‘minimal model’. Acitretin did not influence any parameter of glucose disposition. The area under the insulin-time curve (baseline corrected) was significantly decreased from 1.20 mU·min·l−1 on Day 1 to 0.89 mU·min·l−1 on Day 10, and was 0.91 mU·min·l−1 on Day 24. The model-derived ‘insulin sensitivity’ increased from 13·10−4 l·mU−1·min−1 on Day 1 to 20·10−4 l·mU−1·min−1 on Day 10 and was 18·10−4 l·mU−1·min−1 on Day 24. The results suggest that A increased sensitivity to endogenous insulin. It supports a recent report showing greater insulin sensitivity in patients treated with the synthetic retinoid etretinate.
Similar content being viewed by others
References
Altman PL, Dittmer DS (1971) Blood and other body fluids. 3rd ed. FASEB, Bethesda
Amatuzio DS (1964) Diagnosis: Intravenous glucose tolerance tests. In: Danowsky TS (ed) Diabetes mellitus: Diagnosis and treatment. Vol. I. American Diabetes Association, Inc, New York
Avogaro A, Bristow JD, Bier DM, Cobelli C, Toffolo G (1989) Stable-label intravenous glucose tolerance test minimal model. Diabetes 38: 1048–1055
Beard JC, Bergman RN, Ward WK, Porte D (1986) The insulin sensitivity index in nondiabetic man. Correlation between clamp-derived and IVGTT-derived values. Diabetes 35: 362–369
Bergman RN, Finegood DT, Ader M (1985) Assessment of insulin sensitivity in vivo. Endocr Rev 6: 45–86
Bergman RN, Ider YZ, Bowden CR, Cobelli C (1979) Quantitative estimation of insulin sensitivity. Am J Physiol 236: E667-E677
Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors controlling glucose tolerance in man. J Clin Invest 68: 1456–1467
Bergman RN (1989) Toward physiological understanding of glucose tolerance minimal-model approach. Diabetes 38: 1512–1527
Cobelli C, Pacini G, Toffolo G, Sacca L (1986) Estimation of insulin sensitivity and glucose clearance from minimal model: new insights from labeled IVGTT. Am J Physiol 250: E591-E598
Donner CC, Fraze E, Chen YI, Hollenbeck CB, Foley JE, Reaven GM (1985) Presentation of a new method for specific measurement of in-vivo insulin-stimulated glucose disposal in humans: Comparison of this approach with the insulin clamp and minimal model techniques. J Clin Endocrinol Metab 60: 723–726
Ellis CN, Kang S, Vinik AI, Grekin RC, Cunningham WJ, Voorhees JJ (1987) Glucose and insulin responses are improved in patients with psoriasis during therapy with etretinate. Arch Dermatol 123: 471–475
Ferrannini E, Pilo A (1978) Pattern of insulin delivery after intravenous glucose injection in man and its relation to plasma glucose disappearance. J Clin Invest 64: 243–254
Foley JE, Chen YI, Lardinois CK, Hollenbeck CB, Liu GC, Reaven GM (1985) Estimates of in vivo insulin action in humans: Comparison of the insulin clamp and the minimal model techniques. Horm Metabol Res 17: 406–409
Geiger JM, Czarnetzki BM (1988) Acitretin (Ro 10-1670): Overall evaluation of clinical studies. Dermatologica 176: 182–190
Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, Curry CJ, Fernhoff PM, Grix AW, Lott IT, Richard JM, Sun SC (1985) Retinoid acid embryopathy. N Engl J Med 313: 837–841
Massarella J, Vane F, Buggé C, Rodriguez L, Cunningham WJ, Franz T, Colburn W (1985) Etretinate kinetics during chronic dosing in severe psoriasis. Clin Pharmacol Ther 37: 439–446
Metzler CM, Weiner DL (1985) NONLIN84 — User's Guide, Version V02
Orfanos CE, Ehlert R, Gollnick H (1987) The retinoids — A review of their clinical pharmacology and therapeutic use. Drugs 34: 459–503
Paravicini U, Busslinger A (1983) Determination of etretinate and its main metabolite in human plasma using normal phase high performance liquid chromatography. J Chromatogr (Biomed Applic) 276: 359–366
Paravicini U, Gower M, Geiger JM (1985) Multiple dose pharmacokinetics of Ro 10-1670, the main metabolite of etretinate (Tigason®). In: Saurat JH (ed) Retinoids — New Trends in Research and Therapy. Karger, Basel
Scholer A, Piazezzi A (1976) Mikromethode zur Bestimmung der Glucosekonzentration mit Glukose-Dehydrogenase auf dem Auto-Analyzer. J Clin Chem Clin Biochem 14: 189–195
Vahlquist A, Michaelsson G, Kober A, Sjöholm I, Palmskog G, Petterson U (1981) Retinoid — binding proteins and the plasma transport of etretinate (Ro 10-9359) in man. In: Orfanos CE, Braun-Falco O, Farber EM, Grupper C, Polano MK, Schuppli R (eds), Retinoids — Advances in Basic Research and Therapy. Springer, Berlin
Wiegand UW, Jensen BK (1991) Pharmacokinetics of acitretin in humans. In: Saurat JH (ed) Retinoids: 10 years On. Karger, Basel
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hartmann, D., Forgo, I., Dubach, U.C. et al. Effect of acitretin on the response to an intravenous glucose tolerance test in healthy volunteers. Eur J Clin Pharmacol 42, 523–528 (1992). https://doi.org/10.1007/BF00314862
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00314862